Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All AgesGlobeNewsWire • 05/16/22
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDTGlobeNewsWire • 05/12/22
Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine RequirementsBenzinga • 04/29/22
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/29/22
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022GlobeNewsWire • 04/08/22
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide PoisoningGlobeNewsWire • 03/11/22
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Emergent BioSolutions: Still A Bargain Regardless Of Diminished Growth ForecastsSeeking Alpha • 02/13/22